AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 82 min read$ANGO

AngioDynamics Q1 Earnings Call Highlights

AngioDynamics (ANGO) reported Q1 revenue growth in NanoKnife, up 29% to $8.3M, with probe sales rising 24.1% and capital sales up 53.5%. The company expects AlphaReturn to expand its product line. Gross margin improved to 59.4%, and adjusted EBITDA increased to $5M. The company reaffirmed its fiscal 2027 outlook, expecting revenue of $336M-$341M and adjusted EBITDA of $13M-$16M.

Original reporting
finance.yahoo.com
Published Oct 8, 2026, 2:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 2:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AngioDynamics Q1 Earnings Call Highlights — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$ANGOBullishMed
01

Why it matters

The earnings beat reduces downside risk and may attract short‑term buying, but flat revenue growth tempers enthusiasm.

02

Market read

Earnings release provides fresh data for traders; modest price reaction expected.

03

What to watch

Potential headwinds from tariff uncertainty and reimbursement variability could temper gains.

Relevance 7/10Novelty 7/10Timing: post‑earnings release today

Background

AngioDynamics reported Q1 results, highlighting revenue growth, margin expansion, and reaffirmed FY2027 outlook.

Company-level read

Ticker impact

$ANGOBullishHigh confidence
Context

Q1 earnings released with narrowed loss, margin expansion, and reaffirmed FY2027 guidance.

Expected impact

likely modest upside as market prices in improved loss and reaffirmed guidance

Evidence & confidence

First‑report earnings with better-than‑expected loss, higher gross margin, and unchanged revenue guidance reduce downside risk.

Market effects

Sector

Improved margins may signal strength for the broader med‑tech device sector.

Regional

Limited to U.S. small‑cap healthcare investors.

Global

Low; impact confined to AngioDynamics and peers.

Counterpoint

What could challenge this read

Loss narrowing may already be priced in; focus on flat revenue growth could limit upside.

Key entities

  • Company
    AngioDynamics, Inc.

    Medical device maker (NASDAQ: ANGO).

Read at source← All news

Also covered by

5 outlets

Related articles

OCT 8
$ANGOHighAI 8/10

AngioDynamics Q1 FY2027 net loss narrows to $7.1M

AngioDynamics (NASDAQ: ANGO) reported Q1 FY2027 net loss of $7.1M, down from $10.9M YoY. Net sales rose 6.9% to $80.9M, with Med Tech sales up 13.2%. Adjusted EBITDA was $5.0M. The company announced Eric Honroth as new CEO, effective November 2, 2026. FDA approved IDE for RELIEF study on NanoKnife IRE for benign prostatic hyperplasia. Guidance reiterated: net sales $336M-$341M, adjusted EBITDA $13M-$16M.

stocktitan.net2 min
OCT 8
$ANGOMed

AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability

ANGIODYNAMICS INC (ANGO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability Delivered its eighth consecutive quarter of double-digit Med Tech segment growth and positive adjusted EBITDA LATHAM, N.Y.--(BUSINESS

SEC EDGAR 8-K2 min